Literature DB >> 31060672

[Correlations of Melatonin and Glutathione Levels with Oxidative Stress Mechanism in Parkinson's Disease].

Hui Jun Wei1, Meng DU1, Hong Ying Bai1.   

Abstract

Objective To investigate the changes of serum melatonin(MLT)and glutathione(GSH)levels in patients with Parkinson's disease(PD)and explore their relationships with disease severity,cognitive dysfunction,and sleep disorders. Methods Totally 50 PD patients treated in our center from September 2017 to February 2018 were enrolled as the PD group,and 50 healthy controls matched with age and sex as the control group.The improved Hoehn and Yahr scale was used to assess the severity of PD.The Montreal Cognitive Assessment Scale was used to assess the cognitive function and Pittsburgh's Sleep Quality Index was used to detect the patient's sleep.The serum levels of MLT and GSH were detected by enzyme-linked immunosorbent assay and the results were compared. Results Serum MLT level in the PD group was significantly higher than that in the control group [(84.12±6.58)pg/ml vs.(46.29±9.73)pg/ml,P=0.000],and serum GSH level was significantly lower than that in the control group [(21.07±12.05)μmol/L vs.(77.73±39.90)μmol/L,P=0.000].There was a positive correlation between serum MLT level and H-Y grade(r=0.537,P=0.000),and there was a negative correlation between serum GSH level and H-Y grade(r=-0.596,P=0.000).Serum MLT was negatively correlated with GSH level in PD patients(r=-0.842,P=0.000).The MLT level in PD patients with sleep disorders was significantly higher than in those without sleep disorders [(85.79±6.45)pg/ml vs.(78.84±3.54)pg/ml,P=0.001];the level of GSH in PD patients with cognitive dysfunction was significant lower than in the non-cognitive dysfunction group [(17.47±10.67)μmol/L vs.(26.09±12.23)μmol/L,P=0.011]. Conclusions Serum MLT level increases and GSH level decreases in PD patients.Both MLT and GSH are correlated with PD severity,and there is a negative correlation between MLT and GSH.In addition,PD patients with sleep disorders have higher MLT level and those with cognitive impairment tend to have lower GSH level.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31060672     DOI: 10.3881/j.issn.1000-503X.10775

Source DB:  PubMed          Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao        ISSN: 1000-503X


  3 in total

1.  Network Pharmacology-Based and Molecular Docking-Based Analysis of Suanzaoren Decoction for the Treatment of Parkinson's Disease with Sleep Disorder.

Authors:  Yan-Yun Liu; Li-Hua Yu; Juan Zhang; Dao-Jun Xie; Xin-Xiang Zhang; Jia-Ming Yu
Journal:  Biomed Res Int       Date:  2021-10-08       Impact factor: 3.411

Review 2.  Evidence for Oxidative Pathways in the Pathogenesis of PD: Are Antioxidants Candidate Drugs to Ameliorate Disease Progression?

Authors:  Alexander Leathem; Tamara Ortiz-Cerda; Joanne M Dennis; Paul K Witting
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

Review 3.  Oxidative Stress in Parkinson's Disease: Potential Benefits of Antioxidant Supplementation.

Authors:  Sandro Percário; Aline da Silva Barbosa; Everton Luiz Pompeu Varela; Antônio Rafael Quadros Gomes; Michelli Erica Souza Ferreira; Thayana de Nazaré Araújo Moreira; Maria Fani Dolabela
Journal:  Oxid Med Cell Longev       Date:  2020-10-12       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.